GSK Expands Arexvy Approval for At-Risk Adults
LONDON, United Kingdom, May 20, 2026 GSK has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
LONDON, United Kingdom, May 20, 2026 GSK has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved...
PARIS, FRANCE & TARRYTOWN, NEW YORK, USA | March 24, 2026 Sanofi and Regeneron have announced that Japan’s Ministry...
LEIDEN, NETHERLANDS, March 24, 2026 Pharming Group has announced that Japan’s Ministry of Health, Labour and Welfare has approved...
